Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma

European Oncology and Haematology

Volumn 11, Issue 1, 2015, Pages 21-24

  Domingo Domenech, Eva ^a   Comai, Alessandra ^a   Sureda, Anna ^a  

^a HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

Allogeneic stem cell transplantation; Autologous stem cell transplantation; Brentuximab vedotin; CD30 antigen; Hodgkin's lymphoma; Relapsed refractory disease

Indexed keywords

BRENTUXIMAB VEDOTIN; CARBOPLATIN; CD30 ANTIGEN; ETOPOSIDE; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; MELPHALAN;

ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; COUGHING; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DONOR LYMPHOCYTE INFUSION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ENGRAFTMENT; EVENT FREE SURVIVAL; FATIGUE; FEVER; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REED STERNBERG CELL; SALVAGE THERAPY; SENSORY NEUROPATHY; SEPSIS; THROMBOCYTOPENIA; TUMOR RECURRENCE; TUMOR REGRESSION;

EID: 84973594802     PISSN: 20455275     EISSN: 20455283     Source Type: Journal    
DOI: 10.17925/EOH.2015.11.01.21     Document Type: Article

References (26)

1. Armitage JO, Early stage Hodgkin's lymphoma, N Engl J Med, 2010; 363:653-62
2. Canellos GP, Anderson JR, Propert KJ, Chemotherapy in advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD, N Engl J Med, 1992; 327:1478-84
3. Von Tresckow B, Engert A, Refractory Hodgkin lymphoma, Curr Opin Oncol, 2013;25:463-9
4. Linch DC, Winfield D, Goldstone AH, et al., Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial, Lancet, 1993;341:1051-4
5. Schmitz N, Pfistner B, Sextro M, et al., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial, Lancet, 2002;359:2065-71
6. Martínez C, Canals C, Sarina B, et al., Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation, Ann Oncol, 2013;24:2430-4
7. Thomson KJ, Peggs KS, Blundell E, et al., A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft, Leuk Lymphoma, 2007;48:881-4
8. Younes A, Bartlett NL, Leonard JP, et al., Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas, N Engl J Med, 2010;363:1812-21
9. De Claro A, McGinn K, Kwitkowski V, et al., U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma, Clin Cancer Res, 2012;18:5845-9
10. Fanale MA, Forero-Torres A, Rosenblatt JD, et al., A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies, Clin Cancer Res, 2012;18:248-55
11. Younes A, Gopal AK, Smith SE, et al., Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, J Clin Oncol, 2012;30:2183-9
12. Rothe A, Sasse S, Goergen H, et al., Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience, Blood, 2012;120:1470-2
13. Gibb A, Jones C, Bloor A, et al., Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center, Haematologica, 2013;98:611-4
14. Zinzani PL, Viviani S, Anastasia A, et al., Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials, Haematologica, 2013;98:1232-6
15. Salihoglu A, Elverdi T, Karadogan I, et al., Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey, Ann Hematol, 2015;94:415-20
16. Yang QM, Hong JY, Ko YH, et al., Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia, Onco Targets Ther, 2014;7:1717-22
17. Moskowitz CH, Matasar MJ, Zelenetz AD, et al., Normalization of pre-ASCT, FDG-PET imaging with second-line, non-crossresistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma, Blood, 2012;119:1665-70
18. Sasse S, Rothe A, Goergen H, et al., Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma, Leuk Lymphoma, 2013;54:2144-8
19. Moskowitz A, Schoder H, Gerecitano JF, et al., FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory hodgkin lymphoma, Blood, 2013;122:2099
20. Onishi M, Graf S A, Holmberg L, et al., Brentuximab vedotin administered to platinum-refractory, transplant-naive Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status, Hematol Oncol, 2014 [Epub ahead of print]
21. Moskowitz CH, Nadamanee A, Masszi T, et al., Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, doubleblind, placebo-controlled, phase 3 trial, Lancet, 2015 [Epub ahead of print]
22. Chen R, Palmer JP, Thomas SH, et al., BV enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma, Blood, 2012;119:6379-81
23. Illidge T, Bouabdallah R, Chen R, et al., Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma, Leuk Lymphoma, 2014 [Epub ahead of print]
24. Chen R, Palmer JM, Tsai N, et al., Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma, Biol Blood Marrow Transplant, 2014;20:1864-8
25. Gopal AK, Ramchandren R, O'Connor OA, et al., Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation, Blood, 2012;120:560-8
26. Theurich S, Malcher J, Wennhold K, et al., Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stemcell transplantation induces tumor-specific immunity and sustained clinical remission, J Clin Oncol, 2013;31:59-63